We are happy to share our Study Team’s recent work on the use of PXB-cells for in vitro anti-lipidemic drug screening: “Lipoprotein profile and lipid metabolism of PXB-cells®, human primary hepatocytes from liver-humanized mice: proposal of novel in vitro system for screening anti-lipidemic drugs”.
This fresh publication describes lipoprotein profile and lipid metabolism of PXB-cells®, showing their suitability to screen anti-lipidemic agents. The paper shows that PXB-cells® mainly release triglycerides and cholesterol as VLDL (similar to primary human hepatocytes) in contrast to two other hepatoma cell lines, which mainly release LDL. Fenofibrate (PPARα ligand) suppressed lipoprotein production from PXB-cells® in a dose-dependent manner.
VLDL – very low density lipoprotein; LDL – low density lipoprotein